Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New MRI dye tested against standard for kidney scans

NCT ID NCT07040865

Diagnosis Sponsor: Insel Gruppe AG, University Hospital Bern Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares a newer MRI contrast agent, gadopiclenol, with the standard agent, gadobutrol, for imaging the kidneys and adrenal glands. About 104 adults with incidental findings on scans will receive one of the two agents during a single MRI session. The goal is to see if the newer agent provides equally clear images, which could give doctors another option for these types of scans.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
gadopiclenol (Vueway) and gadobutrol (Gadovist) contrast agents
What this could lead to
If gadopiclenol works as well as the standard contrast agent, it could offer a safe and effective alternative for MRI scans of the kidneys and adrenal glands.
What could go wrong
This is a small, early-phase trial (104 people) comparing two similar agents. It may not show a clear difference, and results may not apply to all patients or imaging types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 104 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * signed informed consent * age ≥18 years * compatibility with magnetic resonance imaging * planned workup of kidney incidental finding or adrenal incidental findings (or both) * body mass index (BMI) \< 31 kg/m2 Exclusion Criteria: * patients with implants that might affect imaging parameters in the region under investigation, as judged by the principal investigator * vulnerable individuals * claustrophobic individuals * individuals that are cognitively impaired or unable to understand the language * pregnant or breastfeeding patients

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Suspect renal and adrenal imaging findings are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Suspect renal and adrenal imaging findings

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Diagnostic, Interventional and Pediatric Radiology Inselspital, University of Bern

    RECRUITING

    Bern, 3010, Switzerland